Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Stomach Neoplasms 3Pancreatic Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 295Capecitabine 209Fluorouracil 183Cisplatin 172Docetaxel 140S 1 (combination) 135Paclitaxel 128Leucovorin 117Irinotecan 110pembrolizumab 104Trastuzumab 75Nivolumab 59apatinib 57Drug Therapy 52sintilimab 46Surgical Procedures, Operative 45Ramucirumab 40Radiotherapy 40Bevacizumab 37Hyperthermic Intraperitoneal Chemotherapy 34Epirubicin 32titanium silicide 31tislelizumab 31Carboplatin 31Gastrectomy 28Cyclophosphamide 27XELOX 25Tegafur 24Folfox protocol 23Albumin-Bound Paclitaxel 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Stomach Neoplasms × gastrin immunogen × Clear all
NCT00020787 2020-08-03

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

Jonsson Comprehensive Cancer Center

Phase 3 Completed
8 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT02521649 2015-08-13

Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

Cancer Advances Inc.

Phase 2 Completed
52 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02518529 2015-08-10

Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients

Cancer Advances Inc.

Phase 2 Completed
41 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡